Abstract
The report of the results of the first generation taxane trials has made evident that these drugs should play a key role in the adjuvant treatment of node-positive operable breast cancer. Although direct comparisons among the different taxane regimens is still lacking, the American AC-paclitaxel dose-dense regimen, the TAC regimen, the French FEC-docetaxel and the Spanish FEC-paclitaxel regimens seem to offer the best results. The TC regimen (docetaxel-cyclophosphamide) is another option, particularly in patients at high risk for cardiac toxicity. Trastuzumab should now be part of the standard adjuvant treatment of HER-2neu positive breast cancer, probably administered in combination with a taxane regimen.